After the first part of this year’s Generics Bulletin Top 50 showed two new players entering the top 10 and the second looked at how firms in the middle of our ranking were faring (see sidebar), this third section of our annual feature reflects positive and negative changes among lower-placed firms that have led to some meaningful movements at the bottom of the table in 2023.
The Generics Bulletin Top 50, Part Three: Final Firms Enjoy Mixed Fortunes
Declines See A Handful Of Players Slide Down The Chart As Others Climb Our Ranking
In the third part of this year’s Generics Bulletin Top 50, we look at how various increases and declines for companies at the bottom of our table have affected their positions in the ranking.
More from Company Rankings
• By
This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.
• By
In the third instalment of this year’s Generics Bulletin Top 50, we look at some of the firms that have been eliminated from the bottom of our table as others have entered the picture.
• By
In the second part of Generics Bulletin’s Top 50, we see some companies rising up the rankings of generics and biosimilars players worldwide, passing others that are moving in the opposite direction.
• By
A deceptively familiar top 10 of generics and biosimilars industry leaders this year belies the significant evolutions seen for major off-patent players over the past 12 months. We reveal the changes under the surface in the first instalment of this year’s Generics Bulletin Top 50.
More from Market Intelligence
• By
Dementia treatment memantine saw the steepest rise in its UK trade price in November, according to the latest figures from WaveData.
• By
After a few months of steep UK price rises for apixaban generics, October saw a correction as average prices headed in the opposite direction, the latest figures from WaveData reveal.
• By
Generics of the schizophrenia treatment Latuda generated more than $4bn in savings a year after their 2022 approval, according to an FDA study.